Market Tracker

12/02 5:16pm ET

Novo Nordisk A/S (NYSE:NVO)

33.93
Delayed Data
As of Dec 02
 +0.38 / +1.13%
Today’s Change
30.89
Today|||52-Week Range
59.00
-41.58%
Year-to-Date
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
Nov 30 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for November 28th
Nov 28 / Zacks.com - Paid Partner Content
3 High-Yield Dividend Stocks to Buy in December
Nov 30 / MotleyFool.com - Paid Partner Content
Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod
Nov 23 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close33.55
Today’s open33.87
Day’s range33.67 - 34.00
Volume3,790,173
Average volume (3 months)4,001,720
Market cap$65.8B
Dividend yield2.67%
Data as of 4:02pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+8.58%
Revenue growth (last year)+1.43%
P/E ratio2.3
Price/Sales9.38
Price/Book12.50

Competitors

 Today’s
change
Today’s
% change
AZNAstraZeneca+0.08+0.31%
AGNAllergan-0.68-0.36%
LLYEli Lilly and Co+1.74+2.64%
ABTAbbott Laboratories+0.30+0.80%
Data as of 4:03pm ET, 12/02/2016

Financials

Next reporting dateFebruary 2, 2017
EPS forecast (this quarter)$0.52
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts